Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for anxiety in stage IV melanoma
NCT00979693Phase 2Withdrawn
- Sponsor
- Multidisciplinary Association for Psychedelic Studies
- Start
- Jan 2012
- Primary completion
- Apr 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in anxiety disorder, sponsored by Multidisciplinary Association for Psychedelic Studies. Planned start Jan 2012; status: withdrawn.
02
Drugs
psilocybin
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT00979693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00979693.